100 Albert Road
Melbourne, VIC 3205
61 3 9670 3273
|Dr. James A. Campbell B.Sc., MBA, Ph.D.||MD, CEO & Exec. Director||419.56k||N/A||N/A|
|Dr. Rebecca Tunstall||VP of Corp. Devel.||N/A||N/A||N/A|
|Mr. Stefan Ross||Company Sec.||N/A||N/A||N/A|
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. The company was incorporated in 2006 and is based in Melbourne, Australia.
Patrys Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.